Skip to main content
Premium Trial:

Request an Annual Quote

454 Life Sciences Receives $2.4M NIH Grant to Reduce Size, Cost of Sequencing Technology

NEW YORK, May 19 (GenomeWeb News) - 454 Life Sciences has received a $2.4 million NIH grant to miniaturize and lower the cost of its DNA sequencing technology, the company said today.


The two-year grant, from the National Human Genome Research Institute, is entitled "Massively Parallel High Throughput, Low Cost Sequencing." 454 Life Sciences, a majority-owned subsidiary of CuraGen, plans to use the funding to further reduce the size of the wells on its PicoTiter plate, to reduce the cost of sequencing per base, and to apply its technology to sequencing a whole fungal genome and large sections of a human genome.


According to the Branford, Conn.-based company, the technology enables researchers to sequence a genome with only one sample preparation.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.